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OBJECTIVES We sought to evaluate the prognostic value of cardiac troponin I (cTnI) in asympto-
matic, ambulatory patients with chronic renal failure treated with long-term hemodial-
ysis.
BACKGROUND Smaller, short-term follow-up studies on this subject have given conflicting results.
METHODS A total of 126 ambulatory patients with chronic renal failure treated with long-term
hemodialysis were followed for two years for all-cause mortality, cardiac mortality, all-cause
hospital admissions and cardiac hospital admissions. Serum cTnI was measured before
dialysis at the time of study entry.
RESULTS One hundred two patients had normal serum levels of cTnI (#0.03 ng/ml) and 24 patients
had elevated levels (0.015 6 0.007 vs. 0.053 6 0.029 ng/ml, p , 0.0001). No significant
difference in all-cause mortality (20 vs. 4 deaths), cardiac mortality (4 vs. 1 death), all-cause
hospital admissions (1.74 6 1.72 vs. 1.25 6 1.19 admissions/patient) or cardiac admissions
(0.52 6 0.89 vs. 0.33 6 0.76 admissions/patient) was present between the patients with
normal cTnI levels and those with elevated cTnI levels. Serum cTnI was not significantly
different between patients who died versus those who survived (0.022 6 0.019 vs. 0.022 6
0.021 ng/ml). Serum cTnI was not an independent predictor of all-cause mortality, cardiac
mortality, all-cause admissions or cardiac admissions. Age (older) and serum albumin (lower)
were independent predictors of all-cause mortality, whereas a history of myocardial infarction
was an independent predictor of cardiac mortality. Serum sodium (lower) was an independent
predictor of all-cause hospital admissions, whereas hypertension and previous myocardial
infarction were independent predictors of cardiac admissions. The best predictors of the time
to death were age (older) and serum sodium level (lower), irrespective of the serum cTnI
levels.
CONCLUSIONS Cardiac troponin I has a limited role in predicting mortality and hospital admissions in
asymptomatic patients with chronic renal failure treated with long-term hemodialysis. (J Am
Coll Cardiol 2001;38:991–8) © 2001 by the American College of Cardiology
The cardiac troponins have emerged as sensitive and specific
markers to detect myocardial injury and infarction, facili-
tating rapid bedside diagnosis and early risk stratification
(1–6). In addition to detecting acute myocardial infarction,
cardiac troponin I (cTnI) and cardiac troponin T (cTnT)
may identify high-risk patients with cardiac diseases who
tend to have subsequent cardiac-related events (7,8). Cor-
onary artery disease is highly prevalent in patients with
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end-stage renal disease and accounts for much of their
observed morbidity and mortality; 50% of patients with
end-stage renal disease die of cardiovascular events (9).
Diagnosing ischemic heart disease in this patient population
remains challenging, because many of these patients present
with abnormal baseline electrocardiograms, frequently com-
pounded by silent or atypical symptoms and a reduced
reliability of creatine kinase-MB isoenzyme (CK-MB), the
conventional marker of myocardial necrosis (9–14). Several
studies have questioned the usefulness of the cardiac tro-
ponins, particularly cTnT, in the presence of renal disease
(14–22).
Because cTnI is exclusively of cardiac origin and, unlike
CK-MB and cTnT, does not express in the skeletal muscle
at any developmental stage, it has been shown to be more
specific for the detection of myocardial injury in patients
with chronic renal failure (14–16,23–28). However, the
prognostic value of elevated serum cTnI to predict subse-
quent cardiac-related events in asymptomatic patients with
renal disease treated with hemodialysis has not been exten-
sively studied with long-term follow-up; the subject has only
been studied with follow-up periods limited to 6 to 12
months (29–31). The present study was conducted to
evaluate the prognostic value of elevated cTnI in asymp-
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tomatic, ambulatory patients with chronic renal failure
treated with long-term hemodialysis. The follow-up period
extended to two years.
METHODS
Patients. The study was approved by the Institutional
Review Board for Human Subjects Research of the Long
Island College Hospital. Written, informed consent was
received from all of the participants. A total of 128 consec-
utive ambulatory patients with chronic renal failure under-
going long-term hemodialysis in the Hemodialysis Unit of
the Long Island College Hospital were included in the
study. The minimal duration of hemodialysis was one year.
Exclusion criteria were: 1) acute coronary syndrome within
three months; 2) chronic stable angina pectoris; 3) chest
pain in the peridialysis period or during four weeks before
enrollment; 4) recent major cardiovascular surgery; and 5)
significant electrocardiographic (ECG) changes suggestive
of myocardial injury or ischemia. The patients were evalu-
ated by a complete medical history and physical examina-
tion, and 12-lead ECGs were recorded. Blood samples were
drawn before dialysis on the patients’ routinely scheduled
hemodialysis day within a three-day time frame. All patients
denied having chest pain at the time their blood was drawn.
Cardiac troponin I, CK-MB, blood urea nitrogen, creati-
nine, calcium, potassium, sodium, albumin, bicarbonate and
chloride levels were measured from all blood samples.
Assays. All of the serum samples were centrifuged for
5 min at 2,300 revolutions per minute to remove any
particulate matter. Plunger-type filters were used to remove
any remaining fibrin. Each tube was labeled with the patient
number and accession number. The technicians who per-
formed the assays were had no knowledge of the clinical
data. Specimens were re-analyzed at random or to verify an
abnormal result to eliminate technical errors. Collected data
were summarized on spreadsheets, with the data sorted in
ascending order by both the patient number and accession
number.
Cardiac troponin I was measured with the ACCESS
troponin I assay (Sanofi Diagnostic Pasteur, Chaska, Min-
nesota). The ACCESS troponin I assay is a two-site
sandwich immunochemiluminescent assay using two mouse
monoclonal antibodies as captured and labeled antibodies
that recognize different epitopes unique to the human cTnI
isoform. The cTnI assay has no detectable cross reactivity
with human skeletal muscle troponin I. By this method,
the serum cTnI level in a normal healthy population is
#0.03 ng/ml, as compared with #0.4 ng/ml by the con-
ventionally used Stratus II fluorometric enzyme immuno-
assay (Dade International, Miami, Florida). Creatine ki-
nase, MB isoenzymes were measured with the ACCESS
CK-MB assay (Sanofi Diagnostic Pasteur). The ACCESS
CK-MB assay is a two-site sandwich immunochemilumi-
nescent assay using two mouse monoclonal antibodies that
specifically recognize CK-MB. By this method, the refer-
ence normal limit of CK-MB is #4 ng/ml.
The analytical sensitivity of each assay was defined as the
smallest concentration that can be distinguished from zero.
Ten replicates of the zero calibrator were run for cTnI and
CK-MB. The analytical sensitivity was calculated using the
10-zero calibrator replicate relative light units measured
2 SD from the zero-curve fit. Both assays generated ana-
lytical sensitivity values within package-insert specifications;
the analytical sensitivity of cTnI was 0.006 ng/ml, against an
expected value of 0.03 ng/ml, and that of CK-MB was
0.09 ng/ml, against an expected value of 0.3 ng/ml. The
precision within runs was calculated based on 10 replicates
of BioRad’s tri-level cardiac control. The procedure adopted
included one analyte per tray, three control levels per analyte
and 10 replicates per control level. The imprecision within
runs for both assays was ,10%.
Serum concentrations of creatinine, calcium, potassium,
sodium, albumin, bicarbonate, chloride and blood urea
nitrogen were measured on a Hitachi 747 Analyzer (Hita-
chi, Indianapolis, Indiana), using routine methods accord-
ing to the manufacture’s protocols.
Follow-up. The study group was classified into two groups
according to the pre-dialysis serum cTnI level on initial
enrollment: 1) patients with normal serum cTnI levels
(#0.03 ng/ml); and 2) patients with elevated serum cTnI
levels (.0.03 ng/ml). All patients were followed up for two
years from the time of their initial enrollment in the study.
The end points studied were: 1) all-cause mortality; 2)
cardiac mortality; 3) all-cause hospital admissions; and 4)
cardiac hospital admissions. Hospital records, outpatient
clinic records and interviews with the patient, family or
primary physician were used for confirmation of the events.
In case of death, the cause of death was verified by reviewing
medical records or death certificates. Death due to acute
myocardial infarction, pulmonary edema, cardiogenic shock
or malignant arrhythmias was deemed cardiac. Sudden
unexplained death was also considered as cardiac. Admis-
sion secondary to acute myocardial infarction, chest pain
suggestive of an acute coronary syndrome, congestive heart
failure, arrhythmias and vascular diseases were considered as
cardiac. Admissions related to vascular access for dialysis
were not included in the admission counts.
Statistical analysis. Continuous variables were expressed
as the mean value 6 SD and were analyzed by the Student
t test. Categorical variables were expressed as percentages
and were analyzed by the chi-square or Fisher exact test, as
appropriate. A two-tailed p value #0.05 was considered
significant. Kaplan-Meier survival analysis was performed to
Abbreviations and Acronyms
CK-MB 5 creatine kinase-MB isoenzyme
cTnI 5 cardiac troponin I
cTnT 5 cardiac troponin T
ECG 5 electrocardiogram or electrocardiographic
ROC 5 receiver-operating characteristic
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evaluate significant differences in all-causes death and car-
diac death between patients with normal cTnI levels and
those with elevated cTnI levels. Receiver-operating charac-
teristic (ROC) curves of serum cTnI, as a predictor of
all-cause mortality, cardiac mortality, all-cause hospital
admissions and cardiac hospital admissions, were plotted.
Logistic regression analysis was performed to identify inde-
pendent predictors of all-cause mortality, cardiac mortality,
all-cause hospital admissions and cardiac hospital admis-
sions. Cox regression analysis was used to determine inde-
pendent variables as the best predictors of time to death. All
of the statistical analyses were performed using SPSS,
version 7.0 (SPSS Inc., Chicago, Illinois).
RESULTS
Two patients received a kidney transplant during the study
period; therefore, they were not included in the analysis.
Of the other 126 patients, 102 had serum levels of cTnI
within normal limits (#0.03 ng/ml) and 24 had elevated
levels (.0.03 ng/ml). The serum cTnI values in the group
of patients with normal levels ranged from 0 to 0.029 ng/ml
(mean [6SD] 0.015 6 0.007 ng/ml), and the serum cTnI
values in the group of patients with elevated levels ranged
from 0.031 to 0.14 ng/ml (mean [6SD] 0.053 6
0.029 ng/ml; p , 0.0001). There was no significant differ-
ence in baseline clinical characteristics between the patients
with normal cTnI levels and those with elevated cTnI levels
(Table 1). Similarly, there was no significant difference in
the baseline biochemical profile between the two groups,
except for a high CK-MB value in the group with elevated
cTnI (Table 2).
Twenty patients (20%) in the normal cTnI group and
four (17%) in the elevated cTnI group died during the
two-year follow-up period. Of the 20 deaths in patients
with normal cTnI, four (20%) were of cardiac origin. Of the
four deaths in patients with elevated cTnI, one (25%) was of
cardiac origin. There was no significant difference in all-
cause mortality and cardiac mortality between the two
groups (Table 3). The causes of cardiac death in the patient
group with normal cTnI were myocardial infarction (n 5 2),
congestive heart failure (n 5 1) and sudden cardiac death
(n 5 1). The only cardiac death in the patient group with
elevated cTnI was due to myocardial infarction.
The total number of all-cause hospital admissions in the
normal cTnI group was 177 (mean [6SD] 1.74 6 1.72
admissions per patient), and the total number of all-cause
admissions in the elevated cTnI group was 30 (mean [6SD]
1.25 6 1.19 admissions per patient; p 5 NS). The numbers
of cardiac admissions were 53 (mean [6SD] 0.52 6 0.89
admissions per patient) and 8 (mean [6SD] 0.33 6 0.76
admissions per patient) in the normal and elevated cTnI
groups, respectively (p 5 NS) (Table 3).
Kaplan-Meier survival analysis showed no significant
differences in all-cause mortality (p 5 0.7292 by the
log-rank statistic) or cardiac mortality (p 5 0.2319 by the
log-rank statistic) between patients with normal cTnI levels
and those with elevated cTnI levels. The ROCs of serum
cTnI as a predictor of all-cause mortality, cardiac mortality,
all-cause hospital admissions and cardiac hospital admis-
sions are shown in Figures 1, 2, 3 and 4. The data points on
all of these ROC plots are near 45°, indicating that serum
cTnI is not a useful tool for predicting any of these end
points. Independent predictors of death were older age
(65.9 6 11.5 vs. 58.1 6 15.7 years in dead vs. alive patients;
Table 1. Baseline Clinical Characteristics: Comparison








Age (yrs) 59.0 6 15.4 62.2 6 14.5
Gender
Male 63 (62%) 14 (58%)
Female 39 (38%) 10 (42%)
Hypertension 84 (82%) 21 (88%)
Diabetes 44 (43%) 10 (42%)
Congestive heart failure 27 (26%) 7 (29%)
Previous myocardial infarction 13 (13%) 3 (12%)
Data are presented as the mean value 6 SD or number (%) of patients. p 5 NS for
all characteristics compared between the two groups.
cTnI 5 cardiac troponin I.
Table 2. Baseline Serum Biochemical Profile: Comparison










Albumin (g/dl) 3.81 6 0.36 3.81 6 0.38 0.98
Bicarbonate (mEq/l) 20.1 6 2.62 20.0 6 2.33 0.96
Blood urea nitrogen (mg/dl) 64.2 6 20.8 63.8 6 21.9 0.93
Calcium (mg/dl) 8.93 6 0.95 9.06 6 0.81 0.52
Chloride (mEq/l) 98.3 6 4.23 99.0 6 3.70 0.41
CK-MB (ng/ml) 3.27 6 1.85 4.18 6 2.25 0.04
Creatinine (mg/dl) 10.30 6 3.10 9.25 6 3.99 0.17
Potassium (mEq/l) 4.77 6 0.67 4.71 6 0.90 0.73
Sodium (mEq/l) 135.8 6 3.61 137.1 6 2.69 0.09
Data are presented as the mean value 6 SD.
CK-MB 5 creatine kinase-MB isoenzyme; cTnI 5 cardiac troponin I.
Table 3. Deaths and Hospital Admissions: Comparison
Between Patients With Normal Cardiac Troponin I Levels and







All-causes deaths 20 (20%) 4 (17%)
Cardiac deaths 4 (20%) 1 (25%)
All-cause admissions
Total 177 30
Per patient 1.74 6 1.72 1.25 6 1.19
Cardiac admissions
Total 53 8
Per patient 0.52 6 0.89 0.33 6 0.76
Data are presented as the number (%) of patients or number and mean value 6 SD
of admissions. p 5 NS for all end points compared between both groups.
cTnI 5 cardiac troponin I.
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p 5 0.008 by the independent t test) and lower serum
albumin levels (3.64 6 0.32 vs. 3.85 6 0.36 g/dl in dead vs.
alive patients; p 5 0.01 by the independent t test). There
was no difference in the serum cTnI levels between patients
who died and those who survived (0.022 6 0.019 vs.
0.022 6 0.021 ng/ml; p 5 0.925). In logistic regression
analysis, serum cTnI was not an independent predictor of
all-cause mortality, cardiac mortality, all-cause hospital
admissions or cardiac hospital admissions. Serum albumin
was the best predictor of all-cause mortality (the lower levels
were associated with higher mortality), and a history of
myocardial infarction was the best predictor of cardiac
mortality. The serum sodium level was an independent
predictor of all-cause hospital admissions (lower levels were
associated with more admissions). Hypertension and previ-
ous myocardial infarction were independent predictors of
cardiac hospital admissions. The best predictors of the time
to death by Cox regression analysis were age (older) (p ,
0.005) and serum sodium level (lower) (p , 0.005), irre-
spective of the serum cTnI levels.
DISCUSSION
Study findings. The present study demonstrates that cTnI
has limited prognostic significance in asymptomatic patients
with chronic renal failure. All-cause mortality, cardiac
mortality, all-cause hospital admissions and cardiac hospital
admissions were not more prevalent in patients with chronic
renal failure with elevated serum cTnI levels than in patients
with normal levels of serum cTnI. Serum cTnI is not a
useful tool for predicting all-cause mortality, cardiac mor-
tality, all-cause hospital admissions and cardiac hospital
admissions. Cardiac TnI was not an independent predictor
of all-cause or cardiac mortality; rather, older age and lower
serum albumin levels were independent predictors of all-
cause mortality, and a history of myocardial infarction was
an independent predictor of cardiac mortality. Similarly,
cTnI was not an independent predictor of all-cause or
cardiac hospital admissions; rather, a lower serum sodium
level was an independent predictor of all-cause hospital
admissions, and hypertension and previous myocardial in-
Figure 1. Receiver-operating characteristic plots of serum cardiac troponin I (cTnI) as a predictor of all-cause death.
Figure 2. Receiver-operating characteristic plots of serum cardiac troponin I (cTnI) as a predictor of cardiac death.
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farction were independent predictors of cardiac hospital
admissions.
Elevation of cTnI in renal failure. Although cTnI has
been considered the most specific among the currently
available biochemical markers of myocardial damage, its
value in the presence of chronic renal failure has been
questioned (28,30,32). The cause of nonspecific elevation of
cTnI is not clear. The current hypotheses addressing such
elevation in chronic renal failure include microinjury to the
myocardium that is undetected by conventional cardiac
imaging, cardiotoxicity due to changes in osmolarity and/or
ion fluxes, increased cardiac preload and myocardial stretch
due to volume overload and nonischemic cardiac injury due
to calcium and oxalate deposition in the heart (30,32).
There is little evidence to suggest that the false-positive rate
of cTnI is related to the magnitude of renal insufficiency,
because no relationship between the serum cTnI concentra-
tion and the serum creatinine value or creatinine clearance
rate has been demonstrated, and no significant differences
has been found between pre- and post-dialysis values of
serum cTnI (28–30,33).
Although the reason for the elevation in serum cTnI in
patients with renal disease is not clear, it may represent the
problems in standardization of cTnI assays. Up to 20-fold
variation in cTnI mass determination may be observed for a
given patient sample when measured by different systems
(34). The manufacturers quote different assay cut-off points
and different studies using the same manufacturer’s assay
have used different cut-off points (4,17). The heterogeneous
nature and biochemical complexity of the serum forms of
cTnI and the difference in the epitome recognition by
different methods have also hindered the standardization of
Figure 3. Receiver-operating characteristic plots of serum cardiac troponin I (cTnI) as a predictor of all-cause hospital admissions.
Figure 4. Receiver-operating characteristic plots of serum cardiac troponin I (cTnI) as a predictor of cardiac hospital admissions.
995JACC Vol. 38, No. 4, 2001 Khan et al.
October 2001:991–8 Cardiac Troponin I in Chronic Renal Failure
serum cTnI assays (34). Consequently, significant ambiguity
often exists in the clinical interpretation of serum cTnI
levels. Furthermore, recent studies have shown differential
stability of cTnI with cTnI-troponin C complexes, which
may also affect the assay results (35). In addition, binding
sites of test antibodies could be altered due to changes in
protein kinase C properties in patients with renal disease,
because protein kinase C phosphorylates troponin I at many
different sites (35).
Cardiac troponin I and prognosis. Although troponin I is
a part of the troponin-tropomyosin complex of the contrac-
tile apparatus in myocytes, the exact nature of its release
from the contractile apparatus of the striated muscle is not
fully understood; probably it is released from the cytosolic
pool into the circulation after necrosis (19). Because cTnI
does not normally circulate in the blood, or circulates only in
minute amounts, and is 13 times more abundant in the
myocardium than is CK-MB, on the basis of weight, the
signal-to-noise ratio associated with cTnI is much more
favorable for the detection of minor amounts of cardiac
necrosis (36). Elevation of cTnI has been shown to be an
important factor for the short- and long-term prognoses of
cardiac mortality and nonfatal cardiac events in patients
with unstable angina (7). As more research is focused on the
clinical utility of cTnI, its role as a prognosis indicator is
expanding. It has been shown that elevated cTnI in acute
myocardial infarction predicts lower reperfusion rates and
an increased risk of primary angioplasty failure (37). Fur-
thermore, it can identify a group of patients with acute
coronary syndromes who would benefit from early catheter-
based coronary interventions (38). Cardiac troponin I has
also been shown to identify a subgroup of patients who are
at high risk of graft failure after cardiac transplantation;
thus, it may be used in the early detection of rejection-
related myocardial injury/necrosis (39). Although not
proven conclusively, microinjury to the myocardium is a
frequently proposed mechanism for elevation of troponins
in the absence of clinical, ECG or echocardiographic
abnormalities. Histologic findings strongly suggest that
minor myocardial cell injury takes place more frequently in
high-risk groups of patients who have a worse prognosis
(4,6,40).
Cardiac troponin I and prognosis in renal failure. Al-
though there have been a few previous reports on the ability
of cTnI to predict future cardiac events in patients with
chronic renal failure who are free of cardiac symptoms, the
published data are sparse and the follow-up periods have
been short (29–31). These studies have demonstrated mixed
results. Apple et al. (29) retrospectively studied 16 patients
receiving long-term hemodialysis to evaluate the prognostic
significance of both cTnI and cTnT over a period of one
year. All of these patients had type I diabetes for a mean
period of 24 years. The end point evaluated was the
occurrence of fatal myocardial infarction. The assay used to
measure serum cTnI was enzyme-linked immunosorbent
assay, and the upper reference limit used was of 0.8 mg/l
(ng/ml). At the time of enrollment, three patients had
serum cTnI levels above the upper reference limit (1.2, 2.4
and 1.6 mg/l) and 12 patients had serum cTnT levels above
the upper reference limit. All three patients with elevated
serum cTnI levels had a history of ischemic heart disease
(unstable angina/coronary artery bypass graft [n 5 1],
myocardial infarction [n 5 1] and unstable angina [n 5 1]).
Patients who had elevated cTnI levels also had elevated
cTnT and CK-MB. During one-year follow-up, four pa-
tients had a fatal myocardial infarction, including those
three with elevated serum cTnI levels; however, it was not
analyzed whether cTnI was an independent predictor of the
fatal myocardial infarction.
In another study, Mockel et al. (30) evaluated the
prognostic significance of cTnI and cTnT in 40 patients
with chronic renal failure. Twenty of these patients had
pre–end-stage renal disease and another 20 had end-stage
renal disease and were treated with hemodialysis. Patients
with any symptoms of angina pectoris during the two weeks
before enrollment or an acute coronary syndrome in the four
weeks before enrollment were not included in the study.
Serum cTnI was measured by immunofluorescence assays
made by two different manufacturers—Dade Stratus II
(Dade International) and Behring OPUS Plus (Behring
Diagnostics, Frankfurt, Germany). The cTnI cut-off values
used in this study were 0.4 mg/l (ng/ml) for the Dade
Stratus II assay and 1.6 mg/l (ng/ml) for the Behring OPUS
Plus assay. In patients with pre–end-stage renal disease,
20% of patients had elevated cTnI levels by the Dade
Stratus II assay and 10% by the Behring OPUS Plus assay,
and in patients with end-stage renal disease treated with
hemodialysis, these rates were 55% and 15%, respectively.
Most of these elevated levels were modest. The follow-up
period was nine months. The primary end points studied
were acute myocardial infarction, all-cause mortality and
hospital admission. One patient had an acute myocardial
infarction, 5 patients died and 22 patients were admitted to
the hospital during the nine-month follow-up period. The
logistic regression model showed that serum cTnI measured
by any assay was not a predictor of any of the primary end
points, considered individually or in combination of two or
all three end points.
In a pilot study, Ropollo et al. (31) examined the
usefulness of cTnI and cTnT as predictors of subsequent
cardiac events in 49 patients with chronic renal failure
treated with dialysis (48 on hemodialysis and 1 on peritoneal
dialysis). An additional 83 patients with renal failure who
were not on dialysis were also examined. Serum cTnI was
measured by the Behring OPUS immunofluorescence assay,
and the cut-off value used was 0.5 ng/ml. The end points
evaluated were unstable angina, acute myocardial infarction
and cardiac death. The follow-up period was six months.
Among the 49 dialysis patients, three had elevated cTnI at
entry (0.94, 1.34 and 14.5 ng/ml). Six patients had signif-
icant cardiac events (myocardial infarction [n 5 4], arrhyth-
mia [n 5 1] and unstable angina [n 5 1]) during the
996 Khan et al. JACC Vol. 38, No. 4, 2001
Cardiac Troponin I in Chronic Renal Failure October 2001:991–8
six-month follow-up period. Of these six patients, three had
elevated cTnI serum levels, but the other three had normal
cTnI serum levels. Three patients died during the six-
month follow-up period. Of these, two had elevated serum
levels of cTnI. All three patients with elevated troponin I
also had elevation of cTnT, and, similarly, all six patients
who developed cardiac events had elevation of cTnT. All 49
patients on dialysis, although asymptomatic at the time of
enrollment, were had chronic stable angina. Other co-
morbid conditions reported in this group of patients were
hypertension (n 5 46), previous myocardial infarction (n 5
10), congestive heart failure (n 5 10), diabetes (n 5 22),
hyperlipidemia (n 5 13) and arrhythmias (n 5 6). Of the 83
patients with renal failure who were not on dialysis, two had
elevated cTnI, but neither of them had any adverse cardiac
events or died during the six-month follow-up period, and
two patients had myocardial infarction, but neither of them
had elevated troponin I levels. Logistic regression analysis
was not performed to determine whether cTnI was an
independent predictor of acute myocardial infarction, un-
stable angina or cardiac death.
In the present study, in which patients with chronic stable
angina were not included, we examined 126 patients with
end-stage renal disease treated with long-term hemodialysis
and prospectively followed for two years for mortality and
hospital admissions. Mortality in patients with chronic renal
failure and elevated cTnI was compared with that in
patients with chronic renal failure and normal cTnI by
Kaplan-Meier survival analysis, and no difference was found
between the two groups. The ROC plots failed to demon-
strate serum cTnI as a useful tool for predicting any of the
end points. In addition, logistic regression analysis was used
to examine the independent predictive value of cTnI for all
four end points, and it was found that cTnI was not an
independent predictive of any end point. Older age and
lower serum albumin levels were independent predictors of
all-cause mortality, whereas a history of myocardial infarc-
tion was an independent predictor of cardiac mortality. A
lower serum sodium level was an independent predictor of
all-cause hospital admissions, whereas hypertension and
previous myocardial infarction were independent predictors
of cardiac hospital admissions. Moreover, Cox regression
analysis showed that the cTnI level was not predictive of the
time to death; rather, older age and lower serum sodium
levels were predictive of the time to death.
Study limitations. Unstable angina and acute myocardial
infarction were not used as study end points. The diagnosis
of unstable angina is purely subjective, and the diagnosis of
acute myocardial infarction in patients with chronic renal
failure may remain uncertain because of the more ambigu-
ous symptoms and the presence of abnormal baseline ECGs
in a number of these patients. The biochemical diagnosis of
acute myocardial infarction is also often difficult in these
patients because of the frequent false-positive elevations of
the cardiac markers. Therefore, the study protocol was
limited to the definitive end points of death and hospital
admissions.
Conclusions. Cardiac troponin I has a limited role in
predicting future mortality and hospital admissions in
asymptomatic, ambulatory patients with chronic renal fail-
ure treated with long-term hemodialysis. The findings of
this study should not be extrapolated to patients with
chronic renal failure who have cardiac symptoms.
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